1. Evaluation of CAR-T cell cytotoxicity against a prostate carcinoma model
- Author
-
A.Kh. Valiullina, E.A. Zmievskaya, A.R. Rakhmatullina, M.N. Zhuravleva, E.E. Garanina, R.R. Miftakhova, A.V. Petukhov, A.A. Rizvanov, and E.R. Bulatov
- Subjects
car-t cells ,chimeric antigen receptor ,solid tumor ,cell model ,prostate carcinoma ,pc-3m ,Science - Abstract
In recent years, a new promising application of adoptive cell therapy (ACT) has been enabled by the development of technologies and the successful clinical use of T cells with a chimeric antigen receptor (CAR-T) for treating patients with malignant B-cell neoplasms. In this study, we obtained CAR-T cells with the second-generation chimeric antigen receptor FMC63-28Z-CAR. The effectiveness of the obtained CAR-T cells against the monolayer of the modified PC-3M prostate carcinoma cell line (Kat+CD19+) was evaluated. A correlation was demonstrated between an increased secretion of the proinflammatory cytokines IFNγ, TNFα, IL6 and a decreased confluence of the tumor cells monolayer. At the same time, a pronounced antitumor effect of CAR-T cells was observed starting from day 5 of coincubation. Thus, the proposed approach can potentially be applied for a preliminary evaluation of the effectiveness of biomedical CAR-T cell products in the treatment of solid tumors.
- Published
- 2022
- Full Text
- View/download PDF